Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
4.400
-0.280 (-5.98%)
At close: Dec 5, 2025, 4:00 PM EST
4.470
+0.070 (1.59%)
After-hours: Dec 5, 2025, 4:47 PM EST
Orchestra BioMed Holdings Stock Forecast
Stock Price Forecast
The 3 analysts that cover Orchestra BioMed Holdings stock have a consensus rating of "Strong Buy" and an average price target of $13.67, which forecasts a 210.68% increase in the stock price over the next year. The lowest target is $10 and the highest is $20.
Price Target: $13.67 (+210.68%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Orchestra BioMed Holdings stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +354.55% | Nov 13, 2025 |
| Barclays | Barclays | Buy Maintains $12 → $11 | Buy | Maintains | $12 → $11 | +150.00% | Nov 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +127.27% | Sep 4, 2025 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 20, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +354.55% | Aug 13, 2025 |
Financial Forecast
Revenue This Year
3.60M
from 2.64M
Increased by 36.43%
Revenue Next Year
3.69M
from 3.60M
Increased by 2.56%
EPS This Year
-1.79
from -1.66
EPS Next Year
-1.60
from -1.79
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 4.2M | 4.8M | ||||
| Avg | 3.6M | 3.7M | ||||
| Low | 3.1M | 2.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 59.2% | 34.2% | ||||
| Avg | 36.4% | 2.6% | ||||
| Low | 18.9% | -26.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.82 | -1.52 | ||||
| Avg | -1.79 | -1.60 | ||||
| Low | -1.74 | -1.61 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.